| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 17.11.2008 (5753
dage). |
Ingen historik.
| Branche | | Ikke-finansielle holdingselskaber (642020). |
| Sidst opdateret den 19.09.2017 og
angivet som gældende fra 19.09.2017 (2525
dage). |
| Historik | Start | Stop |
|---|
| Ikke-finansielle holdingselskaber (642020) | 19.09.2017 | |
| Anden finansiel formidling undtagen forsikring og pensionsforsikring, i.a.n (649900) | 01.01.2017 | 18.09.2017 |
| Hospitaler (861000) | 18.11.2008 | 31.12.2016 |
| Uoplyst (999999) | 17.11.2008 | 17.11.2008 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 11.03.2015 og
angivet som gældende fra 17.11.2008 (5753
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Telefonnummer | | 44448888. |
| Sidst opdateret den 02.01.2017 og
angivet som gældende fra 02.01.2017 (2785
dage). |
Ingen historik.
| Navne | | Novo Nordisk Invest 4 A/S. |
| Sidst opdateret den 02.01.2017 og
angivet som gældende fra 01.01.2017 (2786
dage). |
| Historik | Start | Stop |
|---|
| Novo Nordisk Invest 4 A/S | 01.01.2017 | |
| STENO DIABETES CENTER A/S | 17.11.2008 | 31.12.2016 |
| Tegningsregel | | Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør. . |
| Sidst opdateret den 02.01.2017 og
angivet som gældende fra 02.01.2017 (2785
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | 2 bestyrelsesmedlemmer + |
| 1 bestyrelsesmedlem + 1 direktør |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør. | 02.01.2017 | |
| Selskabet tegnes af bestyrelsesformanden og direktøren i forening eller af bestyrelsesformanden og 1 medlem af bestyrelsen i forening eller af 3 bestyrelsesmedlemmer i forening eller af den samlede bestyrelse | 03.02.2016 | 01.01.2017 |
| Selskabet forpligtes ved underskrift af en anmeldt direktør sammen med bestyrelses formand eller af bestyrelsesformanden i forening med et medlem af bestyrelsen | 21.03.2014 | 02.02.2016 |
Type af revisorbistand:Auditor's report on audited financial statements
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State Authorised Public Accountan
Virksomhedens regnskabsklasse:Reporting class B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor’s responsibilities for the audit of the financial statements" section of this auditor’s report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Novo Nordisk Invest 4 A/S for the financial year 1 January 2023 - 31 December 2023, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the Entity’s financial position at and of the results of its operations for the financial year 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the management commentary. Our opinion on the financial statements døs not cover the management commentary, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management commentary provides the information required by relevant law and regulations. Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements in the relevant law and regulations. We did not identify any material misstatement of the management commentary.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration